GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (NAS:ALLK) » Definitions » Revenue per Share
中文

Allakos (Allakos) Revenue per Share : $0.00 (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Allakos Revenue per Share?

Allakos's revenue per share for the three months ended in Dec. 2023 was $0.00. Allakos's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Allakos's Revenue per Share or its related term are showing as below:

ALLK's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.35
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Allakos Revenue per Share Historical Data

The historical data trend for Allakos's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Revenue per Share Chart

Allakos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial - - - - -

Allakos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Allakos's Revenue per Share

For the Biotechnology subindustry, Allakos's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allakos's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allakos's PS Ratio distribution charts can be found below:

* The bar in red indicates where Allakos's PS Ratio falls into.



Allakos Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Allakos's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=0/86.798
=0.00

Allakos's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )=Revenue (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=0/87.575
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allakos  (NAS:ALLK) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Allakos Revenue per Share Related Terms

Thank you for viewing the detailed overview of Allakos's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Allakos (Allakos) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
Executives
Graham Neil Murray Hamilton director 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Everett Rand Sutherland director 29 HARTWELL AVENUE, LEXINGTON MA 02421
Dolca Thomas director C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Paul Edward Walker director 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Daniel Janney director PO BOX 7414, JACKSON WY 83002
Amy L Ladd director INTUITIVE SURGICAL, INC, 1020 KIFER RD, SUNNYVALE CA 94086
Craig A. Paterson officer: Chief Medical Officer ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Margaret Nell Fitzgerald officer: General Counsel and Secretary ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Steven P James director C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Adam Tomasi officer: COO, CFO and Secretary ZS PHARMA, INC., 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Robert Alexander director, officer: President and CEO 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Harlan Baird Radford officer: Chief Financial Officer C/O EBAY INC., 2145 HAMILTON AVENUE, SAN JOSE CA 95125
Rasmussen Henrik S Md officer: Chief Medical Officer 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
John P Mckearn director, 10 percent owner 5820 NANCY DRIVE, SAN DIEGO CA 92121
Peter A Hudson 10 percent owner 701 COOL SPRINGS BOULEVARD, FRANKLIN TN 37067